Masimo (MASI)
(Delayed Data from NSDQ)
$114.27 USD
-0.78 (-0.68%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $114.34 +0.07 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$114.27 USD
-0.78 (-0.68%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $114.34 +0.07 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
Zacks News
Varian (VAR) & Reliance Group Tie Up to Enhance Cancer Care
by Zacks Equity Research
Varian (VAR) enjoys solid presence in Asia, Latin America and Africa's cancer care space.
Here's Why You Should Hold Medidata Stock in Your Portfolio
by Zacks Equity Research
Medidata's (MDSO) Clinical Cloud platform is likely to provide it a competitive edge in the MedTech space. However, cutthroat competition in the niche space is a headwind.
Will Walgreens (WBA) Q4 Earnings Gain From Overall Strength?
by Zacks Equity Research
Several planned developments, early benefits of new pharmacy contracts as well as an increase in volume are consistently driving growth within Walgreens Boots' (WBA) Retail Pharmacy USA division.
Europe Okays Use of Insulet's (PODD) Omnipod With Fiasp
by Zacks Equity Research
Fiasp's operative efficiency coupled with Insulet's (PODD) Omnipod System will provide a new option for both patients and prescribers to support their diabetes management requirements.
Genomic Health's New Data on Oncotype DX GPS to Boost Uptake
by Zacks Equity Research
Genomic Health (GHDX) continues to see positive developments within the U.S. prostate cancer test business.
Thermo Fisher (TMO) Scales a 52-Week High: What's Driving It?
by Zacks Equity Research
Thermo Fisher (TMO) sees strength in all end markets, categorized either by customer type or geography.
Here's Why You Should Hold Integer Holdings in Your Portfolio
by Zacks Equity Research
Integer Holdings' (ITGR) new strategy to drive sales and profit growth to provide the company with a competitive edge in the MedTech space.
Merit Medical (MMSI) to Acquire Cianna Medical, Shares Up
by Zacks Equity Research
Merit Medical (MMSI) to leverage on Cianna Medical's SAVI and SCOUT platforms. The company plans to retain Cianna Medical's commercial and R&D teams after closure of the transaction.
Boston Scientific Grows on Acquisitions, Product Launches
by Zacks Equity Research
Boston Scientific's (BSX) strategy to extend its existing portfolio through inorganic growth profile has been advancing well. Further, this should help aid the company's top line in the long term.
Abbott's CE Mark for FreeStyle Libre 2 Boosts Diabetes Arm
by Zacks Equity Research
Abbott (ABT) focuses on boosting diabetes care. The latest CE Mark will increase the top-line contributions from the Diabetes unit.
Here's Why You Should Invest in CVS Health (CVS) Stock Now
by Zacks Equity Research
CVS Health's (CVS) solid cash position is encouraging. Strong 2019 PBM selling season is another upside.
Here's Why You Should Buy Inogen (INGN) Stock Right Now
by Zacks Equity Research
Inogen (INGN) is expected to gain from strong international foothold and a raised view for 2018.
Baxter Collaborates With Mayo Clinic to Open Renal Care Center
by Zacks Equity Research
Per the agreement, Baxter (BAX) and Mayo Clinic researchers to form an outpatient clinic for kidney disease management, home dialysis and in-center dialysis services.
Henry Schein's 3 Investments to Fortify Dental Implant Arm
by Zacks Equity Research
Intra-Lock, Medentis Medical and Pro-Cam Implants jointly are likely to prove conducive to growth for Henry Schein's (HSIC) existing implant-based tooth replacement solutions line.
AngioDynamics (ANGO) Q1 Earnings Miss, '19 Sales View Up
by Zacks Equity Research
AngioDynamics (ANGO) sees soft segmental performances in Q1; international sales surge.
Quest Diagnostics Plans a Buyout to Widen TB Testing Suite
by Zacks Equity Research
Quest Diagnostics (DGX) progresses well with regard to its strategy to grow inorganically.
STERIS (STE) Strategic Growth Strong Amid Several Headwinds
by Zacks Equity Research
STERIS (STE) impresses with favorable underlying market trends apart from new products and service offerings. Yet, a severe competition lurking beneath is worrisome for the company.
Quest Diagnostics Inks Lab Service Deal With ReproSource
by Zacks Equity Research
Per agreement with ReproSource, Quest Diagnostics (DGX) to perform laboratory reference testing besides providing supply chain expertise.
Abbott's Troponin-I Wins CE Mark, Vascular Arm Gets a Revamp
by Zacks Equity Research
Abbott's (ABT) life-changing High Sensitive Troponin-I test uses a biomarker, specific to the heart.
Cerner CommunityWorks Selected by Pershing Health System
by Zacks Equity Research
Cerner (CERN) witnesses consistent growth in the Electronic Health Record platform and Revenue Cycle Management solutions.
Hologic's Focal Therapeutics Buyout to Boost Breast Health Arm
by Zacks Equity Research
Hologic (HOLX) progresses with initiatives to boost the Breast Health unit. The recent buyout is likely to widen portfolio and fortify Hologic's position in the breast conserving surgery market.
Here's Why You Should Add Edwards Lifesciences Right Away
by Zacks Equity Research
We are upbeat about the continued strength in Edwards Lifesciences' (EW) THVT business.
Baxter's (BAX) ALTAPORE Bioactive Bone Graft Gets FDA Nod
by Zacks Equity Research
Baxter's (BAX) offers a broad spectrum of surgical products, including bone grafts and substitutes that see lucrative market prospects.
Will LabCorp's (LH) Food Solution Divestment Upset Sales?
by Zacks Equity Research
LabCorp's (LH) lackluster outlook for 2018 includes the earlier-announced divestment of its Food Solutions business.
Neogen (NEOG) Earnings Beat, Revenues Lag Estimates in Q1
by Zacks Equity Research
Accretive integrations and an expanding international footprint drive Neogen's (NEOG) earnings in Q1.